16,515 Shares in Standard BioTools Inc. (NASDAQ:LAB) Acquired by Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Co. Ltd. acquired a new stake in Standard BioTools Inc. (NASDAQ:LAB) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 16,515 shares of the company’s stock, valued at approximately $29,000. Standard BioTools accounts for 0.1% of Takeda Pharmaceutical Co. Ltd.’s holdings, making the stock its 11th largest holding.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LAB. Hollow Brook Wealth Management LLC acquired a new position in shares of Standard BioTools in the 3rd quarter valued at $10,679,000. Charles Schwab Investment Management Inc. increased its holdings in Standard BioTools by 188.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,445,083 shares of the company’s stock valued at $4,719,000 after purchasing an additional 1,597,728 shares during the last quarter. State Street Corp lifted its stake in Standard BioTools by 26.7% in the third quarter. State Street Corp now owns 5,495,136 shares of the company’s stock valued at $10,606,000 after buying an additional 1,157,984 shares during the period. Royce & Associates LP boosted its holdings in Standard BioTools by 136.8% during the fourth quarter. Royce & Associates LP now owns 1,455,503 shares of the company’s stock worth $2,547,000 after buying an additional 840,951 shares during the last quarter. Finally, Barclays PLC grew its position in shares of Standard BioTools by 13.2% during the 3rd quarter. Barclays PLC now owns 3,228,360 shares of the company’s stock worth $6,231,000 after buying an additional 377,195 shares during the period. 53.74% of the stock is owned by institutional investors.

Insider Buying and Selling at Standard BioTools

In related news, Director Casdin Partners Master Fund, L purchased 4,820,959 shares of the business’s stock in a transaction on Friday, February 28th. The shares were purchased at an average price of $1.06 per share, with a total value of $5,110,216.54. Following the completion of the purchase, the director now owns 58,846,780 shares in the company, valued at $62,377,586.80. This represents a 8.92 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 53.10% of the company’s stock.

Standard BioTools Stock Up 2.6 %

LAB opened at $1.19 on Thursday. The stock has a market cap of $450.99 million, a P/E ratio of -1.68 and a beta of 1.62. Standard BioTools Inc. has a 12 month low of $0.99 and a 12 month high of $3.04. The company has a fifty day simple moving average of $1.35 and a 200 day simple moving average of $1.69.

Wall Street Analysts Forecast Growth

Separately, KeyCorp downgraded shares of Standard BioTools from an “overweight” rating to a “sector weight” rating in a research report on Thursday, February 27th.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.